Roche will present new data from its Alzheimer's disease portfolio at the Alzheimer's Association International Conference in London on July 12-15. The data will demonstrate the company's progress in developing next-generation medicines and diagnostic tests for Alzheimer's disease. Five oral presentations will highlight trontinemab, including new long-term data from the Phase Ib/IIa Brainshuttle AD study and the design of the Phase III PrevenTRON study in preclinical Alzheimer's. Roche will also present data on its Elecsys pTau217 blood test, which recently received CE mark certification for use in Alzheimer's diagnosis. The company aims to bring together advanced diagnostics and transformative medicines to benefit Alzheimer's patients through earlier detection and intervention. Roche's Chief Medical Officer, Levi Garraway, stated that the company's goal is to slow, stop, or even prevent the progression of Alzheimer's disease. The company will also present data on its investigational therapeutic approaches, including NLRP3 inhibition, and its approved Elecsys pTau181 blood test for ruling out Alzheimer's disease. Roche is committed to addressing the global burden of Alzheimer's disease and partners with clinicians, scientists, patient advocates, policymakers, and health systems to ensure that advances in research translate into benefits for patients worldwide. The company's Alzheimer's disease portfolio spans several investigational medicines and diagnostics, including trontinemab, nivegacetor, and RG6627, as well as approved and investigational digital and blood-based tests. Roche's presentations at the conference will feature data from its expanding Alzheimer's disease portfolio, including investigational trontinemab, neuroinflammatory approaches, and blood-based diagnostics.